Obesity in Adolescent Men Associated With Increased Risk for Later VTE
Obesity in early adulthood is associated with increased risk for venous thromboembolism later in life, especially pulmonary embolism.
Thrombotic Disorders
THROMBOTIC DISORDERS
FEATURE
LATEST ARTICLES
ETV6 Sequencing Important Among Patients With Inherited Thrombocytopenia, Malignancy
It may be important to sequence ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
DOACs May Increase Risk of Bleeding Complications in Severe COVID-19 Cases
Replacing DOACs with alternative parenteral antithrombotic strategies may help to prevent bleeding complications in patients with SARS-CoV-2 infection.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Anticoagulation May Improve Outcomes in COVID-19 Patients
Longer duration of AC treatment linked to reduced risk for mortality in hospitalized patients.
Patterns of Anticoagulant Therapy Use for Acute Venous Thromboembolism
Investigators compared the use of DOACs with traditional therapies in patients with acute VTE who were either discharged directly from the ED or hospitalized.
High Incidence of Thrombotic Complications in Patients With COVID-19
Investigators assessed rates of VTE and arterial thrombotic complications in patients admitted to the ICU with COVID-19 infection.
Venous Thromboembolism vs Major Bleeding: Case Fatality Rates of Patients With Cancer Receiving Anticoagulation
Case fatality rates may vary among cancer patients with VTE or major bleeding who receive anticoagulant treatments.
Bleeding Risk Assessed With Concomitant Direct Oral Anticoagulants and Verapamil or Diltiazem
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Assessing Infectious, Thrombotic Complications of Splenectomy in Children With Nonmalignant Hematologic Disorders
Splenectomy may be a safe therapeutic options for children with nonmalignant hematologic diseases who have proper vaccinations and follow-up care.
Apixaban Noninferior to Dalteparin for Treatment of Cancer-Associated Venous Thromboembolism
Oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-linked VTE without increasing the risk of major bleeding.
Safety, Efficacy of Apixaban or Rivaroxaban in Upper Extremity Deep Vein Thrombosis
Apixaban or rivaroxaban may be as safe and effective at treating upper extremity deep vein thrombosis as low molecular weight heparin and warfarin.
Quality Improvement Effort Cuts Blood Clots in Brain Injury Patients
Prophylactic anticoagulation protocol improves patient outcomes.
Risk of Systemic Lupus Erythematosus in Patients With Idiopathic Thrombocytopenic Purpura
Patients with idiopathic thrombocytopenic purpura may have a higher risk of systemic lupus erythematosus and should be monitored for incidental lupus.
Rivaroxaban Prevents VTE After Lower-Limb Surgery
Rivaroxaban superior to enoxaparin for preventing major VTE after nonmajor orthopedic surgery.
Integrin Alpha 9 May Modulate Arterial Thrombosis
Compared with controls, the experimental mouse model group was less susceptible to arterial thrombosis in settings using ferric chloride and laser injury–induced thrombosis.
Deep Vein Thrombosis Incidence and Pulmonary Embolism Risk Stratification
High or intermediate PE risk status was linked with lower rates of DVT, but asymptomatic DVT was more often found with high or intermediate PE risk.
Caution Urged for Genetic Screening in Children Suspected of Having Inherited Bleeding Disorders
The authors stated, however, that genetic screening should be used with caution in children.
Combination Treatment May Be Beneficial for Severe Refractory Immune Thrombocytopenia
The primary end point of increased platelet count was achieved by 13 of 18 patients with severe refractory immune thrombocytopenia.
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Mortality, Complications With Therapeutic Plasma Exchange for Acute Immune TTP
Although 76% of patients reported experiencing complications during treatment, the mortality rate per episode was only 3.7%.
Risk Factors for In-Hospital Mortality Among Younger Patients With TTP
Younger age, male sex, and African American ethnicity were found to be independent predictors of in-hospital mortality in younger patients with TTP.
Low-Dose Direct-Acting Oral Anticoagulants Cost-Effective for Thrombosis Prevention in Cancer
Thromboprophylaxis with a low-dose direct-acting oral anticoagulant was associated with lower incidences of cancer-associated thrombosis and bleeding compared with placebo.
Acquired TTP and Septic Disseminated Intravascular Coagulation Distinguishable With Lab Tests
Severe thrombocytopenia, antithrombin levels, and degree of fibrinogen degradation product elevation were found to be distinguishing factors of aTTP.
Emotional, Cognitive Issues Common in Pediatric Patients With Immune Thrombocytopenia
Fatigue, emotional and behavioral symptoms, and executive functioning were found to be associated with quality of life but not with bleeding severity and platelet count.
Risk Score to Prevent Bleeding With Vitamin K Antagonists for Venous Thromboembolism
Researchers developed a risk score to assess risk for vitamin K antagonist-associated bleeding events in patients with venous thromboembolism.
Thrombosis Risk With Immune Thrombocytopenia
In multivariate analysis, history of atrial fibrillation and smoking were associated with risk for thrombosis in patients newly diagnosed with immune thrombocytopenia.
Immune Thrombocytopenia: Durable Responses Noted With Eltrombopag Plus Pulsed Dexamethasone
More than half of evaluable patients who received eltrombopag and pulsed dexamethasone achieved the study’s primary end point.
Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
Rivaroxaban for Children With Acute Venous Thromboembolism
Researchers assessed the efficacy of rivaroxaban in comparison with other standard anticoagulants in children with acute venous thromboembolism.
Time of Day for Taking Warfarin Does Not Matter
Morning or evening administration makes no difference on time outside target INR range
Peripherally Inserted Central Catheters May Increase Venous Thromboembolism Risk in Children
Researchers compared the incidence of venous thromboembolism between children with peripherally inserted central catheters and children with tunneled lines.
Bomedemstat Receives Fast Track Status for Essential Thrombocythemia
The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.
Elderly Patients With Immune Thrombotic Thrombocytopenic Purpura at Increased Risk for Mortality
Elderly patients with immune thrombotic thrombocytopenia purpura often have atypical presentation, which can delay diagnosis and treatment.
Avatrombopag Designated Orphan Drug for Chemo-Induced Thrombocytopenia
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.
Metabolic Syndrome May Up Risk for VTE Recurrence After DVT
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Diagnosis and Management of Thrombocytopenia in Pregnancy
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Blood Type as a Predictor of Response to Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura
Of patients with ADAMTS13 deficiency, those who had type O blood underwent fewer therapeutic plasma exchange procedures compared with patients with type A or B blood.
Caplacizumab Safe, Efficacious With Exacerbation of Acquired Thrombotic Thrombocytopenic Purpura
Researchers evaluated the safety and efficacy of open-label caplacizumab in patients who experienced disease exacerbation during blinded treatment.
Two Easily Measured Biomarkers Could Predict Hemorrhage in Thrombocytopenia
C-reactive protein and urine albumin/creatinine ratio were associated with increased risk of bleeding in patients with thrombocytopenia due to hematologic malignancy.
Addition of Aspirin to Direct-Acting Oral Anticoagulation May Increase Bleeding Risk
Adding aspirin to direct-acting oral anticoagulant therapy without a clear indication may increase bleeding risk without decreasing thrombotic risk.
Eltrombopag May Be Noninferior to Intravenous Immunoglobulin for Presurgery Platelet Count Boost
Of patients receiving eltrombopag, 78.9% reached platelet count targets, compared with 61.1% of patients receiving intravenous immunoglobulin.
Rivaroxaban May Be a Feasible Treatment Option for Thromboembolism in Children
Most individual pharmacokinetic parameter values fell within the expected range irrespective of dosage, VTE outcome, and bleeding events.
Relapse Delayed But Not Prevented With Rituximab for Immune TTP
Patients treated with rituximab experienced improved relapse-free survival at 1 and 3 years but not 5 years after treatment compared with patients receiving corticosteroids alone.
Does Real-World Evidence Support Apixaban Use in Cancer-Related Venous Thromboembolism?
Researchers assessed clinical outcomes with apixaban, low-molecular-weight heparin, and warfarin to treat venous thromboembolism in patients with cancer.
Characterizing Intracranial Hemorrhage Among Patients With Immune Thrombocytopenia
Patients who were older than 65 years, female, or hospitalized in the northeastern United States experienced increased incidence of intracranial hemorrhage.
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms
Vitamin K antagonist treatment was found to decrease splanchnic vein thrombosis recurrence in patients with myeloproliferative neoplasms.
Venous Thromboembolism Outcomes in Patients With Autoimmune Disorders
Researchers found no significant difference in venous thromboembolism recurrence rates between patients with and without autoimmune disorders.
Testosterone Therapy Associated With Increased Risk for Venous Thromboembolism
Risk for venous thromboembolism was increased more than 2-fold for men with and without hypogonadism who received testosterone therapy.
Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Want to read more?
Please login or register first to view this content.
Next post in Thrombotic Disorders
